Endocrine therapy of endometrial cancer.
Lentz
S S
SS
Section on Gynecologic Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157-1065, USA.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D004967:Estrogens; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008593:Menopause; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D011372:Progestins / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000187:drug effects / Q000502:physiology; D011980:Receptors, Progesterone / Q000187:drug effects / Q000502:physiology; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D004967:Estrogens; D011372:Progestins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D013629:Tamoxifen